[1] HUANG Y,HSU J C,KOO H,et al.Repurposing ferumoxytol:diagnostic and therapeutic applications of an FDA-approved nanoparticle[J].Theranostics,2022,12(2):796-816.
[2] 陶祥,赵澄泉.胎儿血管灌注不良的胎盘病理学[J].中华病理学杂志,2020,49(12):1344-1348.
[3] HERNANDEZ-ANDRADE E,HUNTLEY E S,BARTAL M F,et al.Doppler evaluation of normal and abnormal placenta[J].Ultrasound Obstet Gynecol,2022,60(1):28-41.
[4] OPPENHEIMER D C,MAZAHERI P,BALLARD D H,et al.Magnetic resonance imaging of the placenta and gravid uterus:a pictorial essay[J].Abdom Radiol (NY),2019,44(2):669-684.
[5] FLANAGAN E,BELL S.Abdominal Imaging in pregnancy (maternal and foetal risks)[J].Best Pract Res Clin Gastroenterol,2020,44-45:101664.
[6] TOTH G B,VARALLYAY C G,HORVATH A,et al.Current and potential imaging applications of ferumoxytol for magnetic resonance imaging[J].Kidney Int,2017,92(1):47-66.
[7] MEHTA K J.Iron oxide nanoparticles in mesenchymal stem cell detection and therapy[J].Stem Cell Rev Rep,2022,18(7):2234-2261.
[8] JALILI M H,YU T,HASSANI C,et al.Contrast-enhanced MR angiography without gadolinium-based contrast material:clinical applications using Ferumoxytol[J].R Radiol Cardiothorac Imag,2022,4(4):e210323.
[9] WEINBERG D H.Real-time assessment of the development and function of the placenta across gestation to support therapeutics in pregnancy[J].Clin Ther,2021,43(2):279-286.
[10] WU C,BAYER C L.Imaging placental function:current technology,clinical needs,and emerging modalities[J].Phys Med Biol,2018,63(14):14tr01.
[11] SEITER D P,NGUYEN S M,MORGAN T K,et al.Ferumoxytol dynamic contrast enhanced magnetic resonance imaging identifies altered placental cotyledon perfusion in rhesus macaques[J].Biol Reprod,2022,107(6):1517-1527.
[12] CARBILLON L,BENBARA A,FERMAUT M.Maternal vascular malperfusion of the placental bed is a common pathophysiological process that underlies fetal death,early fetal growth restriction,and related hypertensive disorders[J].Am J Obstet Gynecol,2022,227(2):362-363.
[13] CHAPPELL L C,CLUVER C A,KINGDOM J,et al.Pre-eclampsia[J].Lancet,2021,398(10297):341-354.
[14] REDLINE R W,ROBERTS D J,PARAST M M,et al.Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease[J].Am J Obstet Gynecol,2023,228(2):187-202.
[15] CHEN S,SHENOY A.Placental pathology and the developing brain[J].Semin Pediatr Neurol,2022,42:100975.
[16] STOUT J N,ROUHANI S,TURK E A,et al.Placental MRI:development of an MRI compatible ex vivo system for whole placenta dual perfusion[J].Placenta,2020,101:4-12.
[17] 郑昌业,曹满瑞,邹玉坚.产前胎盘MRI功能成像技术的应用进展[J].重庆医学,2020,49(8):1358-1362.
[18] ANDESCAVAGE N,LIMPEROPOULOS C.Emerging placental biomarkers of health and disease through advanced magnetic resonance imaging (MRI)[J].Exp Neurol,2022,347:113868.
[19] DELOISON B,ARTHUIS C,BENCHIMOL G,et al.Human placental perfusion measured using dynamic contrast enhancement MRI[J].PLoS One,2021,16(9):e0256769.
[20] LITTLE J T,BOOKWALTER C A.Magnetic resonance safety:pregnancy and lactation[J].Magn Reson Imaging Clin N Am,2020,28(4):509-516.
[21] MACHADO-RIVAS F,JAIMES C,KIRSCH J E,et al.Image-quality optimization and artifact reduction in fetal magnetic resonance imaging[J].Pediatr Radiol,2020,50(13):1830-1838.
[22] JHA P,PODER L,BOURGIOTI C,et al.Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders[J].Eur Radiol,2020,30(5):2604-2615.
[23] LUDWIG K D,FAIN S B,NGUYEN S M,et al.Perfusion of the placenta assessed using arterial spin labeling and ferumoxytol dynamic contrast enhanced magnetic resonance imaging in the rhesus macaque[J].Magn Reson Med,2019,81(3):1964-1978.
[24] NGUYEN S M,WIEPZ G J,SCHOTZKO M,et al.Impact of ferumoxytol magnetic resonance imaging on the rhesus macaque maternal-fetal interfacedagger[J].Biol Reprod,2020,102(2):434-444.
[25] ZHU A,REEDER S B,JOHNSON K M,et al.Quantitative ferumoxytol-enhanced MRI in pregnancy:A feasibility study in the nonhuman primate[J].Magn Reson Imaging,2020,65:100-108.
[26] ZHU A,REEDER S B,JOHNSON K M,et al.Evaluation of a motion-robust 2D chemical shift-encoded technique for R2*and field map quantification in ferumoxytol-enhanced MRI of the placenta in pregnant rhesus macaques[J].J Magn Reson Imaging,2020,51(2):580-592.
[27] KLIEWER M A,BAGLEY A R,REEDER S B,et al.Normal placental structural anatomy:ultrasound and doppler features elucidated with US-MR image fusion and ferumoxytol-enhanced MRI[J].Abdom Radiol (NY),2023,48(2):744-751.
[28] JACQUIER M,ARTHUIS C,GREVENT D,et al.Dynamic contrast enhanced magnetic resonance imaging:a review of its application in the assessment of placental function[J].Placenta,2021,114:90-99.
[29] FRIAS A E,SCHABEL M C,ROBERTS V H,et al.Using dynamic contrast-enhanced MRI to quantitatively characterize maternal vascular organization in the primate placenta[J].Magn Reson Med,2015,73(4):1570-1578.
[30] WINTERSTEIN A G,THAI T N,NDUAGUBA S,et al.Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy[J].Am J Obstet Gynecol,2023,228(4):465e1-e11.
[31] PERELLI F,TURRINI I,GIORGI M G,et al.Contrast agents during pregnancy:pros and cons when really needed[J].Int J Environ Res Public Health,2022,19(24):16699.
[32] YAO X,ZHANG H,SHI D,et al.Gadolinium retention in the brain of mother and pup mouse:effect of pregnancy and repeated administration of gadolinium-based contrast agents[J].J Magn Reson Imaging,2022,56(3):835-845.
[33] KIETURAKIS A J,WAHAB R A,VIJAPURA C,et al.Current recommendations for breast imaging of the pregnant and lactating patient[J].AJR Am J Roentgenol,2021,216(6):1462-1475.
[34] MATHUR S,PILLENAHALLI MAHESHWARAPPA R,FOULADIRAD S,et al.Emergency imaging in pregnancy and lactation[Formula:see text] [J].Can Assoc Radiol J,2020,71(3):396-402.
[35] WEINREB J C,RODBY R A,YEE J,et al.Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease:Consensus Statements from the American College of Radiology and the National Kidney Foundation[J].Radiology,2021,298(1):28-35.
[36] KLIEWER M A,BOCKOVEN C G,REEDER S B,et al.Ferumoxytol-enhanced magnetic resonance imaging with volume rendering:a new approach for the depiction of internal placental structure in vivo[J].Placenta,2023,131:104-110.
[37] KHAN H,MAY P,KUO E,et al.Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol[J].Ther Adv Hematol,2021,12:20406207211006022.
[38] SHAHROUKI P,KHAN S N,YOSHIDA T,et al.High-resolution three-dimensional contrast-enhanced magnetic resonance venography in children:comparison of gadofosveset trisodium with ferumoxytol[J].Pediatr Radiol,2022,52(3):501-512.
[39] PASRICHA S R,TYE-DIN J,MUCKENTHALER M U,et al.Iron deficiency[J].Lancet,2021,397(10270):233-248.
[40] DAVIDSON E M,SIMPSON J A,FOWKES F J I.The interplay between maternal-infant anemia and iron deficiency[J].Nutr Rev,2023,81(4):480-491.
[41] BASU S,KUMAR D,ANUPURBA S,et al.Effect of maternal iron deficiency anemia on fetal neural development[J].J Perinatol,2018,38(3):233-239.
[42] MEANS R T.Iron deficiency and iron deficiency anemia:implications and impact in pregnancy,fetal development,and early childhood parameters[J].Nutrients,2020,12(2):447.
[43] GEORGIEFF M K.Iron deficiency in pregnancy[J].Am J Obstet Gynecol,2020,223(4):516-524.
[44] COHEN J,KHUDANYAN A,LU J,et al.A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency[J].Am J Hematol,2020,95(12):1572-1577.
[45] SAKASHITA M,NANGAKU M.Ferumoxytol:an emerging therapeutic for iron deficiency anemia[J].Expert Opin Pharmacother,2023,24(2):171-175.
[46] RENELLA P,LI J,PROSPER A E,et al.Ferumoxytol-enhanced cardiac magnetic resonance angiography and 4D flow:safety and utility in pediatric and adult congenital heart disease[J].Children (Basel),2022,9(12):1810.
[47] PONRARTANA S,MOORE M M,CHAN S S,et al.Safety issues related to intravenous contrast agent use in magnetic resonance imaging[J].Pediatr Radiol,2021,51(5):736-747.
[48] DALDRUP-LINK H E,THERUVATH A J,RASHIDI A,et al.How to stop using gadolinium chelates for magnetic resonance imaging:clinical-translational experiences with ferumoxytol[J].Pediatr Radiol,2022,52(2):354-566.
[49] GERB J,STRAUSS W,DERMAN R,et al.Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy[J].Ther Adv Hematol,2021,12:20406207211018042.
[50] LEHRMAN E D,PLOTNIK A N,HOPE T,et al.Ferumoxytol-enhanced MRI in the peripheral vasculature[J].Clin Radiol,2019,74(1):37-50. |
